364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin

@article{Reddy2015364AI,
  title={364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin},
  author={Karunanidhi. Reddy and Christoph Sarrazin and Mark S Sulkowski and Masao Omata and Stefan Zeuzem and Jordan J Feld and Eric J. Lawitz and Robert H. Hyland and Xiao Ding and Jenny C. Yang and Hadas Dvory-Sobol and Steven J. Knox and Phil S Pang and G. M. Subramanian and John McHutchison and Alessandra Mangia and Edward J. Gane and Masashi Chiryu-shi Mizokami and Nezam H. Afdhal and Marc Bourli{\`e}re},
  journal={Gastroenterology},
  year={2015},
  volume={148}
}

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Assessing safety and efficacy of sofosbuvir for the treatment of hepatitis C.

  • Expert opinion on drug safety
  • 2015
VIEW 8 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

The Mexican consensus on the treatment of hepatitis C.

  • Revista de gastroenterologia de Mexico
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.

  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2016
VIEW 1 EXCERPT
CITES METHODS

Similar Papers

Loading similar papers…